Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Sells 61,859 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This trade represents a 8.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Aurinia Pharmaceuticals Trading Down 5.5 %

NASDAQ AUPH opened at $8.19 on Friday. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The stock has a market cap of $1.17 billion, a P/E ratio of -54.60 and a beta of 1.22. The stock has a 50 day simple moving average of $8.10 and a two-hundred day simple moving average of $7.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $27,000. Tower Research Capital LLC TRC raised its position in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $31,000. Finally, Natixis bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth approximately $49,000. Institutional investors own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.